Neoclarityn

Valsts: Eiropas Savienība

Valoda: angļu

Klimata pārmaiņas: EMA (European Medicines Agency)

Aktīvā sastāvdaļa:

desloratadine

Pieejams no:

N.V. Organon

ATĶ kods:

R06AX27

SNN (starptautisko nepatentēto nosaukumu):

desloratadine

Ārstniecības grupa:

Antihistamines for systemic use,

Ārstniecības joma:

Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal

Ārstēšanas norādes:

Neoclarityn is indicated for the relief of symptoms associated with:allergic rhinitisurticaria

Produktu pārskats:

Revision: 46

Autorizācija statuss:

Authorised

Autorizācija datums:

2001-01-15

Lietošanas instrukcija

30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
NEOCLARITYN 5 MG FILM-COATED TABLETS
desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Neoclarityn is and what it is used for
2.
What you need to know before you take Neoclarityn
3.
How to take Neoclarityn
4.
Possible side effects
5.
How to store Neoclarityn
6.
Contents of the pack and other information
1.
WHAT NEOCLARITYN IS AND WHAT IT IS USED FOR
WHAT NEOCLARITYN IS
Neoclarityn contains desloratadine which is an antihistamine.
HOW NEOCLARITYN WORKS
Neoclarityn is an antiallergy medicine that does not make you drowsy.
It helps control your allergic
reaction and its symptoms.
WHEN NEOCLARITYN SHOULD BE USED
Neoclarityn relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages
caused by an allergy, for example, hay fever or allergy to dust mites)
in adults and adolescents
12 years of age and older. These symptoms include sneezing, runny or
itchy nose, itchy palate, and
itchy, red or watery eyes.
Neoclarityn is also used to relieve the symptoms associated with
urticaria (a skin condition caused by
an allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE NEOCLARITYN
DO NOT TAKE NEOCLARITYN
-
if you are allergic to desloratadine, or any of the other ingredients
of this medicine (listed in
section 6) or to loratadine.
WARNINGS AND PR

Produkta apraksts

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Neoclarityn 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect
This medicinal product contains lactose (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets
Light blue, round and embossed film-coated tablets with elongated
letters “S” and “P” on one side and
plain on the other. The diameter of the film-coated tablet is 6.5 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Neoclarityn is indicated in adults and adolescents aged 12 years and
older for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1)
-
urticaria (see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and adolescents (12 years of age and over) _
The recommended dose of Neoclarityn is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents
12 through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Neoclarityn 5 mg film-coated tablets in
children below the age of 12 years
have not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1, or to loratadine.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Renal function